Measuring Patient Benefit From Botulinum Toxin in the Treatment of Dystonia
- 1 December 1997
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 12 (6) , 675-684
- https://doi.org/10.2165/00019053-199712060-00007
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- EuroQol: the current state of playHealth Policy, 1996
- Measuring changes in quality of life following magnetic resonance imaging of the knee: SF-36, EuroQol© or Rosser index?Quality of Life Research, 1995
- VALIDITY OF EUROQOL—A GENERIC HEALTH STATUS INSTRUMENT—IN PATIENTS WITH RHEUMATOID ARTHRITISRheumatology, 1994
- Developing the QALY ConceptPharmacoEconomics, 1993
- Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystoniaNeurology, 1993
- Issues in quality-of-life measurement in clinical trialsControlled Clinical Trials, 1991
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- The dystonias.BMJ, 1990
- Botulinum toxin in spasmodic torticollis.Journal of Neurology, Neurosurgery & Psychiatry, 1988
- Epidemiology of focal and generalized dystonia in Rochester, MinnesotaMovement Disorders, 1988